Publicacións en colaboración con investigadores/as de Centro de Investigación Biomédica en Red de Cáncer (82)

2024

  1. A three-gene expression score for predicting clinical benefit to anti-PD-1 blockade in advanced renal cell carcinoma

    Frontiers in Immunology, Vol. 15

  2. Aptamer functionalization effect on the interaction of sphingomyelin nanoemulsions with plasma proteins. A thermodynamic approach

    Journal of Molecular Liquids, Vol. 397

  3. Genome-wide DNA methylation profiling in tongue squamous cell carcinoma

    Oral Diseases, Vol. 30, Núm. 2, pp. 259-271

  4. Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection

    Cancer Treatment Reviews, Vol. 125

  5. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer

    JAMA network open, Vol. 7, Núm. 4, pp. e247811

2023

  1. A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients

    Biomedicine and Pharmacotherapy, Vol. 159

  2. Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study

    ERJ Open Research, Vol. 9, Núm. 6

  3. Ascites-Derived Organoids to Depict Platinum Resistance in Gynaecological Serous Carcinomas

    International Journal of Molecular Sciences, Vol. 24, Núm. 17

  4. Clinical, molecular, and immune correlates of the Immunotherapy Response Score in patients with advanced urothelial carcinoma under atezolizumab monotherapy: analysis of the phase II IMvigor210 trial

    ESMO Open, Vol. 8, Núm. 4

  5. Clinicopathological Profiles Associated with Discordant RAS Mutational Status between Liquid and Tissue Biopsies in a Real-World Cohort of Metastatic Colorectal Cancer

    Cancers, Vol. 15, Núm. 14

  6. Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET-dysregulated solid tumours

    British Journal of Clinical Pharmacology, Vol. 89, Núm. 3, pp. 1046-1055

  7. Effectiveness of a novel gene nanotherapy based on putrescine for cancer treatment

    Biomaterials Science, Vol. 11, Núm. 12, pp. 4210-4225

  8. Epigenomic analysis reveals a unique DNA methylation program of metastasis-competent circulating tumor cells in colorectal cancer

    Scientific Reports, Vol. 13, Núm. 1

  9. Epigenomic reprogramming of therapy-resistant circulating tumor cells in colon cancer

    Frontiers in Cell and Developmental Biology, Vol. 11

  10. Erratum: Effectiveness of a novel gene nanotherapy based on putrescine for cancer treatment (Biomaterials Science (2023) DOI: 10.1039/d2bm01456d

    Biomaterials Science

  11. Liquid Biopsy Assessment of Molecular Residual Disease in Localized Colorectal Cancer: Is It Ready for Prime Time?

    JAMA Oncology

  12. Liquid biopsies based on cell-free DNA as a potential biomarker in head and neck cancer

    Japanese Dental Science Review, Vol. 59, pp. 289-302

  13. MSIMEP: Predicting microsatellite instability from microarray DNA methylation tumor profiles

    iScience, Vol. 26, Núm. 3

  14. Modelling metastasis in zebrafish unveils regulatory interactions of cancer-associated fibroblasts with circulating tumour cells

    Frontiers in Cell and Developmental Biology, Vol. 11

  15. Models to study CTCs and CTC culture methods

    International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 57-98